NewGenIvf (NIVF) Cash & Equivalents (2022 - 2025)

NewGenIvf has disclosed Cash & Equivalents across 4 years of filings, most recently posting $758621.0 for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 65.73% year-over-year to $758621.0; the TTM figure through Dec 2025 stood at $758621.0 (up 65.73% YoY), while the FY2025 annual figure was $758621.0, up 65.73% from the prior year.
• Cash & Equivalents retreated to $758621.0 in Q4 2025, from $295.3 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for NIVF reached as high as $295.3 billion in Q3 2025 and fell as low as $27556.0 in Q4 2022.
• The 4-year median for Cash & Equivalents is $608180.5 (2024), against an average of $49.2 billion.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 746.04% — and 2025, when it soared 65.73%.
• A 4-year view of Cash & Equivalents shows it stood at $27556.0 in 2022, then jumped by 96.34% to $54104.0 in 2023, then jumped by 746.04% to $457740.0 in 2024, then jumped by 65.73% to $758621.0 in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $758621.0, $295.3 billion, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.